期刊文献+

原发额骨套细胞淋巴瘤一例并文献复习

Primary frontal bone mantle cell lymphoma:report of one case and review of literature
原文传递
导出
摘要 目的探讨原发额骨套细胞淋巴瘤的临床特点、诊断、治疗方案和预后。方法回顾性分析莆田学院附属医院收治的1例原发额骨套细胞淋巴瘤患者的临床资料,并进行文献复习。结果该患者因头晕行影像学检查提示右侧额骨板障内类梭形细胞病变,嗜酸性肉芽肿,后经右额骨嗜酸性肉芽肿切除,病理检查明确诊断为套细胞淋巴瘤。一线使用CHOP方案化疗4个疗程。44个月后复发,二线予GEMOX方案化疗8个疗程后复查PET-CT提示完全缓解,后予沙利度胺维持治疗,患者维持无事件生存。结论原发额骨套细胞淋巴瘤临床上较罕见,发病率低,化疗效果较好。
作者 郑琳琳 许学杰 李冰 吴伟丹 Zheng Linlin;Xu Xuejie;Li Bing;Wu Weidan(Department of Oncology,the Affiliated Hospital of Putian University,Putian 351100,China)
出处 《白血病.淋巴瘤》 CAS 2019年第10期617-620,共4页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献3

二级参考文献50

  • 1Kantajarian HM, O'Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive, in adult acute lymphocytic lenkemia.J Clin Oncol, 2000,18:547-561.
  • 2Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens lymphoblastic lymphoma. Blood, 2004,104:1624-1630.
  • 3Romaguera JE, Fayad L, Rodriquez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive manlle-cell lymphoma with rituximab plus hyper-CVAD ahenmting with rituximab plus high-dose methotrexate and cytarahine. J Clin Oncol, 2005,23: 7013-7023.
  • 4van Dalen EC, van der Pal HJ, Caron HN, et al. Different dosage schedules for reducing carditoxicity in cancer patients receiving anthracyciine chemotherapy. Cochrane Database Syst Rev,2009,7: CD005008.
  • 5Kzhl BS, Longo WL, Eiekoff JC, et al. Maintenance rituximab following induction ehemoimmunotherapy may prolong progression- free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oneology Network. Ann Oncol,2006,17:1418-1423.
  • 6Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.J Clin Oneol, 2008,26:2767-2778.
  • 7Trifilio SM, Pi J, Zook, J, et al. Effectiveness of a single 3-rag rasburicase dose for the management of hyperuricemia in patients with hematologic malignancies. Bone Marrow Transplant,2001,46:800-805.
  • 8Hemline O, Hoster E, Walewski J, et al. Ahemating courses of 3 x CHOP and 3 x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantlecell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual MeetingAbstracts),2010,116:Abstract 110.
  • 9Kahl BS, Chang J, Eickhoff J, et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase 1I study from the Wisconsin Oncology Network. Blood (ASH Annual Meeting Abstracts),2008,112:Abstract 265.
  • 10Veleade [package insert]. Cambridge: Millennium Pharmaceuticals, Inc. 2009.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部